Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis-The Role of Biochemical Response as a Dynamic
Chang Liu1,2,3, Zuohong Ma2,3,4, Pengfei Li2,3,5
1Central Laboratory, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China.
Alimentary Pharmacology & Therapeutics
|November 3, 2025
Abstract
No abstract available in PubMed .
More Related Videos
09:55Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
Published on: May 16, 2020
4.1K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.9K
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
395
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
395
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
